ALYSON NGUYEN: Open Payments
NPI 1801508106 · HUNTINGTON BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,204 in 288 payments from 21 companies in 2025. Trend: 2023 $466 · 2024 $4,022 · 2025 $7,204
Food & beverage: $7,204
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 28 | $1,073 |
| ABBVIE INC. | 45 | $960 |
| Neurocrine BioSciences, Inc. | 29 | $920 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 33 | $823 |
| Teva Pharmaceuticals USA, Inc. | 40 | $719 |
| Lundbeck LLC | 21 | $457 |
| Vanda Pharmaceuticals Inc. | 19 | $444 |
| Alkermes, Inc. | 13 | $415 |
| Otsuka America Pharmaceutical, Inc. | 12 | $306 |
| Axsome Therapeutics, Inc. | 11 | $257 |
Products named: VRAYLAR, INGREZZA, SPRAVATO, CAPLYTA, REXULTI, AUSTEDO XR, FANAPT, ARISTADA.
Industry payments across CA — which companies pay providers there.
